Eli Lil­ly’s new, $1B pain drug racks up an­oth­er promis­ing round of PhI­II pain da­ta

Eli Lil­ly spent close to a bil­lion dol­lars to get its hands on the mi­graine drug las­mid­i­tan, bag­ging CoLu­cid in Jan­u­ary as a way to build its pain drug fran­chise. And it’s pay­ing off to­day with an­oth­er round of pos­i­tive Phase III da­ta as Lil­ly nav­i­gates it way to an ex­pect­ed reg­u­la­to­ry fil­ing next year.

Lil­ly hopes to dif­fer­en­ti­ate this drug by fo­cus­ing on the drug’s abil­i­ty to de­liv­er fast re­lief from se­vere pain. And while its new Phase III da­ta is dogged by high place­bo re­spons­es, re­searchers were able to nail down sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ments in re­sponse in the drug arms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.